COGT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cogent Biosciences Inc (COGT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive long-term potential due to its regulatory progress and analyst optimism, the lack of immediate catalysts, insider selling, and weak financial performance suggest holding off for now.
The technical indicators show a mixed picture. The MACD is positive and expanding, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the RSI is neutral at 64.126, and the stock is trading near its resistance level of 39.893. The stock has a 60% chance to decline in the short term based on candlestick pattern analysis.
Regulatory progress for bezuclastinib across multiple indications.
Analysts have raised price targets significantly, with Piper Sandler and H.C. Wainwright projecting a price of $
Hedge funds are heavily buying, with a 2828.69% increase in the last quarter.
Insiders are selling, with a 946.09% increase in the last month.
Weak financial performance in Q4 2025, with no revenue and a net loss of -88.42M.
No recent news or significant event-driven catalysts.
Stock trend analysis suggests potential short-term downside (-1.44% in the next week, -4.62% in the next month).
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -88.42M, though the loss improved by 555.46% YoY. EPS also improved to -0.59, up 391.67% YoY. Despite these improvements, the financials remain weak with no revenue generation.
Analysts are optimistic, with multiple firms raising price targets recently. Piper Sandler and H.C. Wainwright have a target of $52, and JPMorgan has a target of $67. The focus on regulatory approvals and commercial readiness is seen as a positive long-term driver.
